Why Science Animation for Immunotherapy Matters

Immunotherapy mechanisms are often hard to explain with words alone. They involve specialized immune cells, synthetic peptides, complex biological pathways, and unique patient populations. In this case, EO2463 operates using a novel concept – molecular mimicry from microbial peptides – to selectively target malignant B cells.

Our science animation for immunotherapy helped distill this into a compelling, digestible story. It supported Enterome’s communications during a critical fundraising period.

EO2463: A New Direction in B Cell Cancer Treatment

EO2463 is built on Enterome’s proprietary OncoMimics™ platform, which uses microbial-derived peptides to activate pre-existing memory CD8+ T cells. These peptides mimic specific B cell markers: CD20, CD22, CD37, and CD268. Once activated, the T cells attack the malignant B cells that express these markers.

Unlike traditional cancer antigens, OncoMimics™ bypass thymic deletion, a natural checkpoint that typically prevents the immune system from attacking self-proteins. This allows EO2463 to trigger a stronger, more targeted immune response, while remaining safe and well tolerated.

Clinical Results and Funding Milestone

Enterome presented interim results from the SIDNEY Phase 1/2 trial at the International Conference on Malignant Lymphoma (ICML) in June 2025:

  • 60% complete response rate when EO2463 was combined with lenalidomide and rituximab (R2)
  • Clear anti-tumor activity from EO2463 monotherapy in early dosing
  • Exceptional safety and tolerability across patient groups

These results positioned Enterome to raise $19 million from investors including:

  • The Institute for Follicular Lymphoma Innovation (IFLI) – $9 million
  • Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP) and others – $10 million

Read the full press release on Enterome’s website.

Science Animation for Immunotherapy: A Strategic Asset

By combining data-driven storytelling with visual clarity, our science animation for immunotherapy helped Enterome:

  • Simplify EO2463’s unique mechanism
  • Demonstrate value to both scientific and investor audiences
  • Enhance their visibility during conference presentations and meetings

In today’s competitive biotech landscape, strong science needs equally strong communication tools. Visual storytelling is not just “nice to have”. It can be the difference between being understood or overlooked.

If you’re preparing for fundraising, clinical milestones, or conference season, we can help. Contact us to discuss your project.